The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Molecular mechanisms for tumour resistance to chemotherapy
Abstract
Summary: Chemotherapy is one of the prevailing methods used to treat malignant tumours, but the outcome and prognosis of tumour patients are not optimistic. Cancer cells gradually generate resistance to almost all chemotherapeutic drugs via a variety of distinct mechanisms and pathways. Chemotherapeutic resistance, either intrinsic or acquired, is caused and sustained by reduced drug accumulation and increased drug export, alterations in drug targets and signalling transduction molecules, increased repair of drug‐induced DNA damage, and evasion of apoptosis. In order to better understand the mechanisms of chemoresistance, this review highlights our current knowledge of the role of altered drug metabolism and transport and deregulation of apoptosis and autophagy in the development of tumour chemoresistance. Reduced intracellular activation of prodrugs (e.g. thiotepa and tegafur) or enhanced drug inactivation by Phase I and II enzymes contributes to the development of chemoresistance. Both primary and acquired resistance can be caused by alterations in the transport of anticancer drugs which is mediated by a variety of drug transporters such as P‐glycoprotein (P‐gp), multidrug resistance associated proteins, and breast cancer resistance protein. Presently there is a line of evidence indicating that deregulation of programmed cell death including apoptosis and autophagy is also an important mechanism for tumour resistance to anticancer drugs. Reversal of chemoresistance is likely via pharmacological and biological approaches. Further studies are warranted to grasp the full picture of how each type of cancer cells develop resistance to anticancer drugs and to identify novel strategies to overcome it.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Apoptosis: controlled demolition at the cellular level
Taylor, R. C., Cullen, S. P., & Martin, S. J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2312 · Cited by 2,624
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
Autophagy Suppresses Tumorigenesis through Elimination of p62
Mathew, R., Karp, C. M., Beaudoin, B., Vuong, N., Chen, G., Chen, H.-Y., Bray, K., Reddy, A., Bhanot, G., Gelinas, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.048 · Cited by 1,719
Termination of autophagy and reformation of lysosomes regulated by mTOR
Yu, L., McPhee, C. K., Zheng, L., Mardones, G. A., Rong, Y., Peng, J., Mi, N., Zhao, Y., Liu, Z., Wan, F., et al. (2010) · Nature · doi:10.1038/nature09076 · Cited by 1,544
Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
Ouyang, L., Shi, Z., Zhao, S., Wang, F. ‐., Zhou, T. ‐., Liu, B., & Bao, J. ‐. (2012) · Cell Proliferation · doi:10.1111/j.1365-2184.2012.00845.x · Cited by 1,452
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.350 · Cited by 1,204
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Austin Doyle, L., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,051
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
Sharom, F. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.105 · Cited by 973
Sui, X., Kong, N., Ye, L., Han, W., Zhou, J., Zhang, Q., He, C., & Pan, H. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.11.019 · Cited by 958
Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG
Liang, C., Feng, P., Ku, B., Dotan, I., Canaani, D., Oh, B.-H., & Jung, J. U. (2006) · Nature Cell Biology · doi:10.1038/ncb1426 · Cited by 919
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Multiple molecular mechanisms for multidrug resistance transporters
Higgins, C. F. (2007) · Nature · doi:10.1038/nature05630 · Cited by 860
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790
Mitochondrial apoptosis: killing cancer using the enemy within
Lopez, J., & Tait, S. W. G. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.85 · Cited by 784
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Cascorbi, I. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114164 · Cited by 747
GOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
The mitochondrial pathways of apoptosis
Estaquier, J., Vallette, F., Vayssiere, J.-L., & Mignotte, B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_7 · Cited by 637
Fulda, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24064 · Cited by 615
The MRP family of drug efflux pumps
Kruh, G. D., & Belinsky, M. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206953 · Cited by 614
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
The ABC transporter structure and mechanism: perspectives on recent research
Jones, P. M., & George, A. M. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3336-9 · Cited by 578
The BCL-2 protein family, BH3-mimetics and cancer therapy
Delbridge, A. R. D., & Strasser, A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.50 · Cited by 531
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
Galmarini, C., Mackey, Jr., & Dumontet, C. (2001) · Leukemia · doi:10.1038/sj.leu.2402114 · Cited by 511
A change of strategy in the war on cancer
Gatenby, R. A. (2009) · Nature · doi:10.1038/459508a · Cited by 402
Wijnholds, J., de Lange, E. C. M., Scheffer, G. L., van den Berg, D.-J., Mol, C. A. A. M., van der Valk, M., Schinkel, A. H., Scheper, R. J., Breimer, D. D., & Borst, P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8267 · Cited by 360
ROLE OF ABCG2/BCRP IN BIOLOGY AND MEDICINE
Krishnamurthy, P., & Schuetz, J. D. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141238 · Cited by 356
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Cascorbi, I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.009 · Cited by 355
Hirohashi, T., Suzuki, H., & Sugiyama, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15181 · Cited by 347
c-FLIP, a master anti-apoptotic regulator.
Safa, A. R. (2012) · PubMed · Cited by 346
The dynamic control of signal transduction networks in cancer cells
Kolch, W., Halasz, M., Granovskaya, M., & Kholodenko, B. N. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3983 · Cited by 339
Curtis, M. J., & Wolpert, T. J. (2004) · The Plant Journal · doi:10.1111/j.1365-313x.2004.02040.x · Cited by 333
Mitochondria—Judges and Executioners of Cell Death Sentences
Bhola, P. D., & Letai, A. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.019 · Cited by 326
ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy
Ding, X.-W., Wu, J.-H., & Jiang, C.-P. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.02.012 · Cited by 323
Labi, V, & Erlacher, M. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.20 · Cited by 295
Klein, M., Burla, B., & Martinoia, E. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.11.056 · Cited by 275
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P., & Bentires-Alj, M. (2015) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 272
Glutathione transferases and development of new principles to overcome drug resistance
Sau, A., Pellizzari Tregno, F., Valentino, F., Federici, G., & Caccuri, A. M. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.05.012 · Cited by 271
Belinsky, M. G., Chen, Z., Shchaveleva, I., Zeng, H., & Kruh, G. D. (2002) · PubMed · Cited by 262
Pharmacokinetic variability of anticancer agents
Undevia, S. D., Gomez-Abuin, G., & Ratain, M. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1629 · Cited by 258
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas
Mestre-Escorihuela, C., Rubio-Moscardo, F., Richter, J. A., Siebert, R., Climent, J., Fresquet, V., Beltran, E., Agirre, X., Marugan, I., Marín, M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-026500 · Cited by 246
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
Ashkenazi, A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80420 · Cited by 239
Jin, Z., McDonald, E. R., Dicker, D. T., & El-Deiry, W. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405538200 · Cited by 237
Targeting apoptosis for anticancer therapy
Fulda, S. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.002 · Cited by 231
Um, H.-D. (2016) · Oncotarget · doi:10.18632/oncotarget.6405 · Cited by 219
Discoveries and controversies in BCL‐2 protein‐mediated apoptosis
Zheng, J. H., Viacava Follis, A., Kriwacki, R. W., & Moldoveanu, T. (2016) · The FEBS Journal · doi:10.1111/febs.13527 · Cited by 207
Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Gimenez-Bonafe, P., Tortosa, A., & Perez-Tomas, R. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166600 · Cited by 196
Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells
Song, J., Qu, Z., Guo, X., Zhao, Q., Zhao, X., Gao, L., Sun, K., Shen, F., Wu, M., & Wei, L. (2009) · Autophagy · doi:10.4161/auto.5.8.9996 · Cited by 195
Metabolism and Transport of Oxazaphosphorines and the Clinical Implications
Zhang, J., Tian, Q., Yung Chan, S., Chuen Li, S., Zhou, S., Duan, W., & Zhu, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1080/03602530500364023 · Cited by 189
Self-citationDeath receptors as targets in cancer
Micheau, O., Shirley, S., & Dufour, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12238 · Cited by 189
Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies
Ediriwickrema, A., & Saltzman, W. M. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/ab500084g · Cited by 183
Molecular basis of multidrug transport by ABC transporters
Seeger, M. A., & van Veen, H. W. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.12.004 · Cited by 170
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Shukla, S., Chen, Z.-S., & Ambudkar, S. V. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.005 · Cited by 168
The Bcl-2 family: structures, interactions and targets for drug discovery
Kvansakul, M., & Hinds, M. G. (2015) · Apoptosis · doi:10.1007/s10495-014-1051-7 · Cited by 168
Radogna, F., Dicato, M., & Diederich, M. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.018 · Cited by 162
Mechanism of autophagic regulation in carcinogenesis and cancer therapeutics
Panda, P. K., Mukhopadhyay, S., Das, D. N., Sinha, N., Naik, P. P., & Bhutia, S. K. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.02.013 · Cited by 143
Yoon, J., Ahn, S., Lee, B., Jung, S.-H., & Oh, S. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.029 · Cited by 111
Aguilar, C., & Latour, S. (2015) · Journal of Clinical Immunology · doi:10.1007/s10875-015-0141-9 · Cited by 109
Sturm, I., Stephan, C., Gillissen, B. F., Siebert, R., Janz, M., Radetzki, S., Jung, K., Loening, S. A., Dörken, B., & Daniel, P. T. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401782 · Cited by 107
Spatial dynamics of TRAIL death receptors in cancer cells
Twomey, J. D., Kim, S.-R., Zhao, L., Bozza, W. P., & Zhang, B. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.001 · Cited by 105
Wise, J. F., Berkova, Z., Mathur, R., Zhu, H., Braun, F., Tao, R.-H., Sabichi, A. L., Ao, X., Maeng, H. M., & Samaniego, F. (2013) · Blood · doi:10.1182/blood-2012-12-471094 · Cited by 100
Sugatani, J. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rv-096 · Cited by 98
IAP antagonists: promising candidates for cancer therapy
Mannhold, R., Fulda, S., & Carosati, E. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.003 · Cited by 98
Mattia, E. D., Cecchin, E., & Toffoli, G. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.003 · Cited by 97
Schuyer, M., van der Burg, M. E. L., Henzen-Logmans, S. C., Fieret, J. H., Klijn, J. G. M., Look, M. P., Foekens, J. A., Stoter, G., & Berns, E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2101 · Cited by 95
Review of recent studies on resistance to cytotoxic deoxynucleoside analogues
Jordheim, L. P., & Dumontet, C. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.004 · Cited by 92
Fujimoto, A., Takeuchi, H., Taback, B., Hsueh, E. C., Elashoff, D. A., Morton, D. L., & Hoon, D. S. �. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2932 · Cited by 91
Cytochrome P450 and Anticancer Drugs
Fujita, K. (2005) · Current Drug Metabolism · doi:10.2174/138920006774832587 · Cited by 91
Kruh, G. D., Belinsky, M. G., Gallo, J. M., & Lee, K. H. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9039-1 · Cited by 82
Autophagy Suppresses Tumorigenesis through Elimination of p62
Mathew, R., Karp, C. M., Beaudoin, B., Vuong, N. D., Chen, G., Chen, H., Bray, K., Reddy, A., Bhanot, G. V., Gélinas, C., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.046 · Cited by 73
New light on multidrug binding by an ATP-binding-cassette transporter
Shilling, R. A., Venter, H., Velamakanni, S., Bapna, A., Woebking, B., Shahi, S., & van Veen, H. W. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.02.008 · Cited by 66
IAPs: Modular regulators of cell signalling
Budhidarmo, R., & Day, C. L. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.12.002 · Cited by 58
Frequent LOH at Chromosome 12q22‐23 and Apaf‐1 Inactivation in Glioblastoma
Watanabe, T., Hirota, Y., Arakawa, Y., Fujisawa, H., Tachibana, O., Hasegawa, M., Yamashita, J., & Hayashi, Y. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00474.x · Cited by 55
Pharmacogenomics of Drug-Metabolizing Enzymes and Drug Transporters in Chemotherapy
Bosch, T. M. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-205-2_5 · Cited by 51
Zhou, Y., Sun, K., Ma, Y., Yang, H., Zhang, Y., Kong, X., & Wei, L. (2014) · Scientific Reports · doi:10.1038/srep05382 · Cited by 51
Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL)
Fulda, S. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4471-6458-6_8 · Cited by 38
Wang, F., Liu, J., Robbins, D. F., Morris, K., Sit, A., Liu, Y., & Zhao, Y. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0559-8 · Cited by 38
Patel, J. N. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000134 · Cited by 32
Targeting protein kinases to reverse multidrug resistance in sarcoma
Chen, H., Shen, J. K., Choy, E., Hornicek, F. J., & Duan, Z. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.011 · Cited by 31
Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL)
Wu, J., Siddiqui, J. A., Nihal, M., Vonderheid, E. C., & Wood, G. S. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.10.020 · Cited by 27
Cited by
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-02198-8 · Cited by 565
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., & López-Romero, J. M. (2019) · Nanomaterials · doi:10.3390/nano9040638 · Cited by 527
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
Nanotechnology for Cancer Therapy Based on Chemotherapy
Zhao, C.-Y., Cheng, R., Yang, Z., & Tian, Z.-M. (2018) · Molecules · doi:10.3390/molecules23040826 · Cited by 330
Metadata
- Authors
- Pan, S., Li, Z., He, Z., Qiu, J., & Zhou, S.
- Venue
- Clinical and Experimental Pharmacology and Physiology
- Publisher
- Wiley
- Published
- 2016-07-04
- Volume
- 43
- Issue
- 8
- Pages
- 723-737
- ISSN
- 0305-1870 (ISSN-L)
- 1440-1681
- OpenAlex
- W2462715093
- Cited by
- 401
- References
- 91
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.